论文部分内容阅读
本文采用双厂牌ＥＩＡ试剂平行检测ＨＣＶ血清盘，发现并联筛检试验的特异度保持在９６％，灵敏度则分别由９１％（甲）、８２％（乙）提高到９４％（甲／乙）；符合率由９３％、８８％提高到９５％（甲／乙）。由预期（＋）性血清中检出甲／乙试剂呈＋／－或－／＋反应模式的血清共４份。另检测冻存的临床血清样本２６例中，甲试剂全为（＋）性，Ｃ．Ｏ．Ｉ．Ｘ±２ＳＤ介于１．９２～６．０６；乙试剂（＋）性２５例，Ｃ．Ｏ．Ｉ．Ｘ±２ＳＤ介于０．８２～９．９８，后者±２ＳＤ下值低于Ｃ．Ｏ．Ｉ．１．０的界限水平。结果表明宜倡导用不同厂牌试剂并联筛检法可减少假阴性温检，有益于献血员筛检和保证临床安全供血，降低经输血传播丙型肝炎。
In this paper, we used dual label EIA reagents to detect HCV serum disks in parallel and found that the specificity of parallel screening tests was maintained at 96% and the sensitivity increased from 91% (A) and 82% (B) to 94% (A / B) ; The coincidence rate increased from 93% and 88% to 95% (A / B). A total of 4 serums were obtained from the expected (+) serum with a +/- or - / + response to the A / B reagent. Another test of frozen clinical serum samples in 26 cases, A reagent all (+), C. O. I. X ± 2SD ranged from 1.92 to 6.06; B reagent (+) in 25 cases, O. I. X ± 2SD ranged from 0.82 to 9.98, which was lower than C at ± 2SD. O. I. 1.0 of the threshold level. The results showed that it is appropriate to advocate parallel screening with different brands of reagents can reduce the false-negative temperature test, blood donors benefit screening and to ensure the safety of clinical blood supply, reduce the transmission of hepatitis C through blood transfusion.